18355-96-9Relevant articles and documents
Process improvement in the production of a pharmaceutical intermediate using a reaction calorimeter for studies on the reaction kinetics of amination of a bromopropyl compound
Sano, Takahiro,Sugaya, Toru,Kasai, Masaji
, p. 169 - 174 (1998)
A synthetic process to produce a pharmaceutical intermediate, [3-(dimethylamino)propyl]triphenylphosphonium bromide (1), was established in the laboratory. Process safety evaluations did not show any severe problems. In order to scale up to plant scale, w
Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
-
Page/Page column 24, (2008/06/13)
The present invention provides a novel polymorphic form of olopatadine hydrochloride ([(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride), a selective histamine H1-receptor antagonist that is used for the treatment of ocular symptoms of seasonal allergic conjunctivitis. The present invention also provides novel methods for producing olopatadine on a large scale, and in a manner that is cost effective, provides a low level of impurities and eliminates the need to use the costly and dangerous base, butyllithium, which is used in prior art reactions for making olopatadine. The present invention further provides novel processes for carrying out a large scale production of 3-dimethylaminopropyltriphenylphosphonium bromide and its corresponding hydrobromide salt, which are employed in the production of olopatadine, and pharmaceutically acceptable salts of olopatadine.
Therapeutic agents
-
, (2008/06/13)
Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which R1, R2 and R3 independently represent hydrogen, hydroxy, halo, alkyl or alkoxy; ALK1 represents a C2-6 alkylene chain optionally substituted by one or more C1-2 alkyl groups; Y represents a piperidine ring which is attached through nitrogen to ALK1 ; R4 represents hydrogen or a C1-4 alkyl group; the broken line in --- represents a bond, or is absent and the free valency on Y is taken up by hydrogen and the free valency on CR4 is taken up by hydrogen or a C1-4 alkyl group; ALK2 is absent or represents a C1-4 alkylene chain optionally substituted by one or more C1-2 alkyl groups; and R5 and R6 independently represent hydrogen, alkyl, phenyl, alkyl (optionally substituted) or R5 and R6 together with the nitrogen atom to which they are attached represent a saturated 3-7 membered heterocyclic ring (with a proviso); are disclosed which are antiinflammatory, antiallergic and immunomodulatory agents. Compositions containing these compounds and processes to prepare these compounds are also disclosed.